PAHC FINANCIAL STATEMENTS

Phibro Animal Health Corporation — balance sheet, income statement and cash flow trends

PAHCPhibro Animal Health Corporation

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue1.5 B $+26.0%

Gross Profit487.3 M $+29.2%

Operating Income184 M $+93.4%

EBITDA225.3 M $+80.1%

Net Income95.2 M $+199.6%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PAHC	26.0%	32.5%	15.0%	6.3%
BHC	-9.9%	75.9%	60.0%	-13.5%
ECILC	-2.3%	34.3%	14.8%	-3.6%
GENIL	16.3%	23.4%	14.3%	4.0%
ROVI	-3.4%	63.2%	27.0%	17.8%
HLN	-26.7%	61.5%	25.2%	12.6%
Industry median	7.5%	60.6%	18.2%	4.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PAHC	26.0%	32.5%	15.0%	6.3%
XERS	41.5%	81.6%	14.7%	3.8%
COLL	19.9%	60.7%	76.6%	9.4%
PRGO	-3.6%	34.2%	-29.7%	-43.5%
HROW	26.2%	74.1%	11.7%	-5.6%
PCRX	4.6%	79.3%	16.1%	0.7%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity361.8 M $25%
Current Liabilities281.9 M $20%
Long-term Liabilities801.4 M $55%

Key Figures

YoY change

Total Assets1.4 B $+9.7%

Total Liabilities1.1 B $+3.0%

Total Equity361.8 M $+36.0%

Cash & ST Investments77.5 M $+10.1%

Total Debt787.4 M $+2.3%

Net Debt732.5 M $+3.2%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PAHC	3.17	217.6%	3.15	25.0%
BHC	1.32	-1,010.0%	3.71	-8.4%
ECILC	1.73	5.9%	-0.10	81.0%
GENIL	1.33	41.0%	1.10	52.6%
ROVI	3.66	17.0%	0.09	72.8%
HLN	0.92	52.3%	3.50	50.3%
Industry median	2.22	46.3%	1.24	45.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PAHC	3.17	217.6%	3.15	25.0%
XERS	2.12	286.9%	-1.61	3.3%
COLL	1.71	258.6%	0.63	18.9%
PRGO	2.72	152.3%	-2.78	31.3%
HROW	2.48	1,047.4%	6.55	6.8%
PCRX	4.73	62.9%	1.77	54.1%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow66.1 M $-24.2%

Capital Expenditures53.4 M $+39.6%

Free Cash Flow12.8 M $-74.0%

Dividends Paid-19.5 M $-200.1%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PAHC	4.4%	0.9%	3.6%	69.4%
BHC	16.2%	11.3%	4.9%	-119.7%
ECILC	13.9%	16.1%	7.1%	-391.0%
GENIL	6.4%	-6.7%	4.8%	162.4%
ROVI	24.4%	15.5%	8.9%	137.0%
HLN	12.5%	11.3%	1.2%	99.0%
Industry median	15.2%	11.6%	2.5%	84.3%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PAHC	4.4%	0.9%	3.6%	69.4%
XERS	15.4%	15.0%	0.4%	404.1%
COLL	41.6%	41.4%	0.2%	441.7%
PRGO	4.5%	2.6%	2.0%	-10.4%
HROW	5.7%	5.3%	0.3%	-101.6%
PCRX	19.4%	18.1%	1.3%	2,767.9%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on PAHC

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.